The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression (P-TRD)
Phase of Trial: Phase II/III
Latest Information Update: 20 Dec 2018
At a glance
- Drugs Psilocybin (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Acronyms P-TRD
- Sponsors COMPASS Pathways
- 23 Jun 2018 Status changed from planning to recruiting.
- 12 Dec 2017 New trial record
- 06 Dec 2017 According to a COMPASS Pathways media release, this trial is expected to begin in the first quarter of 2018.